This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vanhoutte, P. M. Search for Related Content PubMed PubMed Citation Articles by Vanhoutte, P. M.

Hypertension, Vol 21, 747-751, Copyright © 1993 by American Heart Association

ARTICLES

Is endothelin involved in the pathogenesis of hypertension?

PM Vanhoutte
Baylor College of Medicine, Center for Experimental Therapeutics, Houston, TX 77030.

Endothelins are a family of potent vasoconstrictor peptides released by endothelial cells. The production of endothelin-1 (ET-1) can be stimulated by aggregating platelets and angiotensin II. It is inhibited by increases in intracellular concentration of cyclic GMP. ET-1 causes biphasic changes in arterial blood pressure and of peripheral resistance in several vascular beds: an initial transient decrease (due to release of nitric oxide, prostacyclin, or both from the endothelium) followed by a sustained increase (mainly due to direct activation of vascular smooth muscle). The vasoconstriction induced by the peptide is inhibited by increases in cyclic GMP. Few studies, except in pregnant women with preeclampsia or eclampsia, indicate that the circulating levels of the peptide are augmented in hypertension. Likewise, the information available on changes in responsiveness to endothelins in blood vessels from hypertensive animals is controversial. Until the effect of selective antagonists on the production or action of the peptide can be determined in hypertensive patients, caution must be exerted when implying a role for endothelin in the pathophysiology of hypertension.

This article has been cited by other articles:

				T. Asai, T. Ohkubo, T. Katsuya, J. Higaki, Y. Fu, M. Fukuda, A. Hozawa, M. Matsubara, H. Kitaoka, I. Tsuji, et al. Endothelin-1 Gene Variant Associates With Blood Pressure in Obese Japanese Subjects: The Ohasama Study Hypertension, December 1, 2001; 38(6): 1321 - 1324. [Abstract] [Full Text] [PDF]

				L. Tiret, O. Poirier, V. Hallet, T. A. McDonagh, C. Morrison, J. J. V. McMurray, H. J. Dargie, D. Arveiler, J.-B. Ruidavets, G. Luc, et al. The Lys198Asn Polymorphism in the Endothelin-1 Gene Is Associated With Blood Pressure in Overweight People Hypertension, May 1, 1999; 33(5): 1169 - 1174. [Abstract] [Full Text] [PDF]

				K. Munter, H. Ehmke, and M. Kirchengast Maintenance of blood pressure in normotensive dogs by endothelin Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1022 - H1027. [Abstract] [Full Text] [PDF]

				P. Moreau Endothelin in hypertension: A role for receptor antagonists? Cardiovasc Res, September 1, 1998; 39(3): 534 - 542. [Abstract] [Full Text] [PDF]

				P. Moreau, H. Takase, C. F. Kung, S. Shaw, and T. F. Luscher Blood Pressure and Vascular Effects of Endothelin Blockade in Chronic Nitric Oxide–Deficient Hypertension Hypertension, March 1, 1997; 29(3): 763 - 769. [Abstract] [Full Text]

				P. Sventek, A. Turgeon, and E. L. Schiffrin Vascular Endothelin-1 Gene Expression and Effect on Blood Pressure of Chronic ETA Endothelin Receptor Antagonism After Nitric Oxide Synthase Inhibition With L-NAME in Normal Rats Circulation, January 7, 1997; 95(1): 240 - 244. [Abstract] [Full Text]

				R. A. Preston, I. Singer, and M. Epstein Renal Parenchymal Hypertension: Current Concepts of Pathogenesis and Management Arch Intern Med, March 25, 1996; 156(6): 602 - 611. [Abstract] [PDF]

				P. Sventek, J.-S. Li, K. Grove, C. F. Deschepper, and E. L. Schiffrin Vascular Structure and Expression of Endothelin-1 Gene in L-NAME–Treated Spontaneously Hypertensive Rats Hypertension, January 1, 1996; 27(1): 49 - 55. [Abstract] [Full Text]

				E. L. Schiffrin Endothelin: Potential Role in Hypertension and Vascular Hypertrophy Hypertension, June 1, 1995; 25(6): 1135 - 1143. [Abstract] [Full Text]

				J. E. Bird, S. Moreland, T. L. Waldron, and J. R. Powell Antihypertensive Effects of a Novel Endothelin-A Receptor Antagonist in Rats Hypertension, June 1, 1995; 25(6): 1191 - 1195. [Abstract] [Full Text]

				T. Kitazono, D. D. Heistad, and F. M. Faraci Enhanced Responses of the Basilar Artery to Activation of Endothelin-B Receptors in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, April 1, 1995; 25(4): 490 - 494. [Abstract] [Full Text]

				K. A. H. Kaasjager, H. A. Koomans, and T. J. Rabelink Effectiveness of Enalapril Versus Nifedipine to Antagonize Blood Pressure and the Renal Response to Endothelin in Humans Hypertension, April 1, 1995; 25(4): 620 - 625. [Abstract] [Full Text]

				Y. Hirata, H. Hayakawa, E. Suzuki, K. Kimura, K. Kikuchi, T. Nagano, M. Hirobe, and M. Omata Direct Measurements of Endothelium-Derived Nitric Oxide Release by Stimulation of Endothelin Receptors in Rat Kidney and Its Alteration in Salt-Induced Hypertension Circulation, February 15, 1995; 91(4): 1229 - 1235. [Abstract] [Full Text]